Yorvipath Receives Final FDA Approval

The U.S. Food and Drug Administration (FDA) has granted final approval for Yorvipath (palopegteriparatide-ycmt), developed by Ascendis Pharma (ASND), for the treatment of hypoparathyroidism in adults. Yorvipath is the first once-daily subcutaneous injection designed to continuously release into the body, maintaining physiological levels of parathyroid hormone (PTH 1-34). This approval marks a significant development in the market, especially after Takeda's Natpara, a competing drug, was permanently withdrawn due to safety and device issues, leaving a void in treatment options.

Regulatory Re-evaluation Overcomes Manufacturing Challenges

The drug's path to approval faced some regulatory hurdles. In April 2023, the FDA issued a Complete Response Letter (CRL), citing concerns regarding manufacturing and the precision of the dosage delivery device, which delayed the launch. However, Ascendis Pharma diligently addressed these issues by improving the manufacturing process and providing additional data. In November 2023, they resubmitted the application, ultimately securing final approval. This demonstrates that the drug meets the stringent quality standards of regulatory agencies, alleviating market concerns about the drug's safety and device accuracy.

Transforming Treatment Paradigm for Chronic Patients

Hypoparathyroidism is a rare endocrine disorder caused by complications from thyroid surgery, leading to abnormal regulation of calcium and phosphorus levels in the body. Traditional treatment involves daily high doses of calcium and active vitamin D supplements, which can expose patients to serious long-term risks such as kidney stones and chronic kidney failure. Yorvipath goes beyond temporary supplementation by addressing the underlying hormone deficiency, potentially reducing long-term complications and significantly improving patients' quality of life, establishing itself as a new standard of care.

Blockbuster Sales and Commercial Success

Since its launch in the U.S. market, Yorvipath has achieved rapid commercial growth despite its high price of $285,000 per patient per year (WAC). In 2025, the drug generated record annual sales of €477 million in the global market. In the first quarter of 2026, it generated €197 million, contributing significantly to profitability. This exemplifies how an innovative drug with a strong market position in the endocrine disease market can rapidly expand prescriptions and maximize revenue.

Strengthening Financial Stability Through Non-Dilutive Funding

To mitigate financial risks during commercialization, Ascendis Pharma entered into a royalty agreement with Royalty Pharma for $150 million. Ascendis Pharma receives an upfront payment of $150 million from Royalty Pharma in exchange for a royalty of 3% of Yorvipath's U.S. sales. This royalty right terminates when the investment is recouped up to a maximum of two times (1.65 times upon meeting certain conditions). This strategic financing is considered an excellent example of venture capital (VC) practices, as it avoids diluting shareholder value while quickly securing the liquidity needed for large-scale marketing and the development of subsequent pipelines.